everolimus
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
De Novo Renal Transplantation
Conditions
De Novo Renal Transplantation
Trial Timeline
Sep 1, 2006 → —
NCT ID
NCT00464399About everolimus
everolimus is a phase 3 stage product being developed by Novartis for De Novo Renal Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00464399. Target conditions include De Novo Renal Transplantation.
What happened to similar drugs?
9 of 15 similar drugs in De Novo Renal Transplantation were approved
Approved (9) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00655252 | Pre-clinical | Completed |
| NCT05108740 | Pre-clinical | Completed |
| NCT05252585 | Approved | Active |
| NCT03525834 | Approved | Completed |
| NCT02962414 | Phase 3 | Active |
| NCT02842749 | Approved | Completed |
| NCT02429869 | Approved | Completed |
| NCT02539459 | Phase 2 | Terminated |
| NCT02687958 | Phase 2 | UNKNOWN |
| NCT02376985 | Phase 3 | Completed |
| NCT02338609 | Approved | Completed |
| NCT02236572 | Phase 2 | Terminated |
| NCT02273752 | Phase 2 | Terminated |
| NCT02201212 | Phase 2 | Completed |
| NCT01864070 | Phase 1 | Withdrawn |
| NCT01997255 | Phase 2 | Withdrawn |
| NCT02096107 | Approved | Completed |
| NCT02017860 | Phase 2 | Completed |
| NCT01636466 | Phase 3 | Terminated |
| NCT01609673 | Pre-clinical | Terminated |
Competing Products
19 competing products in De Novo Renal Transplantation